• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

H125 reaffirms funds are sufficient to deliver key data

by alex | Jan 30, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Poised for several pivotal clinical events in 2025

by chantal | Jan 13, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Fundraise extends cash into H226 beyond key catalysts

by chantal | Dec 6, 2024 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Genmab strikes second GlyMab deal

by chantal | Dec 4, 2024 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Report 31st October 2024

by alex | Oct 31, 2024 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

AGM Presentation 2024

by admin | Oct 25, 2024 | Investor Presentations

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy